José Luiz de Lima Filho

José Luiz de Lima Filho

Auto-generated profile, based on publicly available information

José Luiz de Lima Filho

Universidade Federal de Pernambuco (UFPE)

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Renal Failure
Verified
Journal Article
Open access
RBRodrigo Bezerra
Rodrigo Bezerra
FTFlávio Teles
Flávio Teles
PMPolyana Bezerra Mendonca
Polyana Bezerra Mendonca
TDTedla Damte
Tedla Damte
ALAndrew Likaka
Andrew Likaka
JFJosé Luiz de Lima Filho
José Luiz de Lima Filho
Early reports indicate that AKI is common during COVID-19 infection. Different mortality rates of AKI due to SARS-CoV-2 have been reported, based on the degree of organic dysfunction and varying fr...

30 June 2020 in Immunological Investigations
Verified
Journal Article
Closed access
EMEdilson Leite de Moura
Edilson Leite de Moura
ASAna Caroline Santos
Ana Caroline Santos
DSDenise Macedo da Silva
Denise Macedo da Silva
BSBruna Brandão dos Santos
Bruna Brandão dos Santos
DFDiego de Siqueira Figueredo
Diego de Siqueira Figueredo
ESElaine Souza
Elaine Souza
This study investigated the relationship between single-nucleotide polymorphisms (SNPs) in cytokine genes and the susceptibility to Squamous Intraepithelial Lesions (SIL), cervical cancer and HPV i...

24 March 2020 in Immunological Investigations
Verified
Journal Article
Closed access
JFJean Moisés Ferreira
Jean Moisés Ferreira
LSLeandro Douglas Silva Santos
Leandro Douglas Silva Santos
SOSusana Paiva Oliveira
Susana Paiva Oliveira
BSBárbara Rayssa Correia dos Santos
Bárbara Rayssa Correia dos Santos
ASAna Caroline Santos
Ana Caroline Santos
JFJosé Luiz de Lima Filho
José Luiz de Lima Filho
Background: Chikungunya virus (CHIKV) is a global concern, inducing chikungunya fever and trigging an arthritogenic chronic phase beyond some severe forms. Outcomes of CHIKV infections in humans are dependent on genetic variations. Here, a systematic review was performed to show evidence of genetic variations on infection outcomes of patients. Methods: Searches were performed in Scopus, SciELO, MEDLINE/PubMed, Web of Science, OneFile (GALE), Periódicos CAPES and ScienceDirect Journals databases. The PICOS approach was used to assess the eligibility of records. A meta-analysis was also conducted to show an association between described alleles/genes and CHIKV infection outcome. Results: Reviews of genetic variants were conducted on genes: CD 209, OAS1, OAS2, OAS3, MIF, TLR-3, TLR-7, TLR-8, MYD-88, KIR, HLA-B; HLA-C; DRB1 and DQB1. Studies were performed on Gabon, Singapore, and India, including Indians, Malay, Gabonese and Chinese ethnicities and published between 2009–2017. The meta-analysis was performed with DRB1 *01; *03; *04; *07; *10; *11; *13; *14 and *15 and DQB1 *02; *03; *05 and *06 alleles with Indian population sample. Sampling power was >80% and a significant positive association between DRB1*14 and CHIKV infection was found (OR = 1.67, 95% CI = 1.04–2.67; p = .03). Conclusion: Majority of the studies were conducted in India. Meta-analysis suggests that DRB1*14 is related to the susceptibility of symptomatic CHIKV infection in Indian population. The literature about CHIKV infection and genetic variations is scarce. The precise role of genetic variation in CHIKV is not clear yet. Further studies are necessary to provide more concrete evidences.

1 October 2020 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
ASAlexandre Cesar Vieira Sales
Alexandre Cesar Vieira Sales
ISIsaura Isabelle Fonseca Gomes da Silva
Isaura Isabelle Fonseca Gomes da Silva
MLMatheus Cb Leite
Matheus Cb Leite
LCLeandro L Coutinho
Leandro L Coutinho
RRRenata Bac Reis
Renata Bac Reis
FSFabricio Oliveira Souto
Fabricio Oliveira Souto
Introduction: MicroRNA-21 (miRNA-21) has been described as one of the most significantly upregulated miRNAs in human breast cancer. However, limited knowledge exists on miRNA-21 expression in breast cancer tissue after neoadjuvant chemotherapy (NAC). Purpose: The aim of this study was to assess miRNA-21 expression in the tumor tissues of Brazilian patients with breast cancer who underwent NAC and its correlation with clinicopathological variables. Patients and Methods: Utilizing qRT-PCR, miRNA-21 expression in tumor tissue was measured in a cohort of female patients with breast cancer who underwent NAC. The correlation of miRNA-21 expression with breast cancer molecular subtypes and other clinicopathological variables was also assessed. Results: A total of 55 patients were included in the study, and 28 (50.9%) underwent NAC. miRNA-21 was upregulated in patients with breast cancer, regardless of previous exposure to chemotherapy, molecular subtypes, tumor-node-metastasis (TNM) staging and lymph node status of the axilla. miRNA-21 expression did not differ between patients with breast cancer who achieved a pathologic complete response after NAC and healthy controls. Conclusion: miRNA-21 was upregulated in the tumor tissue of Brazilian patients with breast cancer regardless of NAC treatment, which reinforces its role as an “oncomiR” and a potential biomarker.

1 April 2018 in Gene
Verified
Journal Article
Closed access
KFKatyana Kaline Silva Ferreira
Katyana Kaline Silva Ferreira
EGEnéas Ricardo de Morais Gomes
Enéas Ricardo de Morais Gomes
JFJosé Luiz de Lima Filho
José Luiz de Lima Filho
CCCarlos Henrique Madeiros Castelletti
Carlos Henrique Madeiros Castelletti
DMDanyelly Martins
Danyelly Martins

14 August 2020 in Preparative Biochemistry & Biotechnology
Verified
Journal Article
Closed access
MOMarcella Cardoso Lemos de Oliveira
Marcella Cardoso Lemos de Oliveira
APAnderson José Paulo
Anderson José Paulo
CLCarolina de Albuquerque Lima
Carolina de Albuquerque Lima
JFJosé Luiz de Lima Filho
José Luiz de Lima Filho
CSCristina Maria Souza-Motta
Cristina Maria Souza-Motta
APAna Lucia Figueiredo Porto
Ana Lucia Figueiredo Porto
Lovastatin is a drug in the statin class which acts as a natural inhibitor of 3-hydroxy-3-methylglutaryl, a coenzyme reductase reported as being a potential therapeutic agent for several diseases: Alzheimer’s, multiple sclerosis, osteoporosis and due to its anti-cancer properties. Aspergillus terreus is known for producing a cholesterol reducing drug. This study sets out to evaluate the production of lovastatin by Brazilian wild strains of A. terreus isolated from a biological sample and natural sources. Carbon and nitrogen sources and the best physicochemical conditions using factorial design were also evaluated. The 37 fungal were grown to produce lovastatin by submerged fermentation. A. terreus URM5579 strain was the best lovastatin producer with a level of 13.96 mg/L. Soluble starch and soybean flour were found to be the most suitable substrates for producing lovastatin (41.23 mg/L) and biomass (6.1 mg/mL). The most favorable production conditions were found in run 16 with 60 g/L soluble starch, 15 g/L soybean flour, pH 7.5, 200 rpm and maintaining the solution at 32 °C for 7 days, which led to producing 100.86 mg/L of lovastatin and 17.68 mg/mL of biomass. Using natural strains and economically viable substrates helps to optimize the production of lovastatin and promote its use.